Alamo Group Inc
Change company Symbol lookup
Select an option...
ALG Alamo Group Inc
BCPC Balchem Corp
HE Hawaiian Electric Industries Inc
ASGN ASGN Inc
MAN ManpowerGroup Inc
APG APi Group Corp
CWST Casella Waste Systems Inc
FCFS Firstcash Holdings Inc
STVN Stevanato Group SpA
OSH Oak Street Health Inc
Go

Industrials : Machinery | Small Cap Blend
Company profile

Alamo Group Inc. is engaged in designing, manufacturing and servicing quality vegetation management and infrastructure maintenance equipment for governmental, industrial and agricultural use. The Company operates through two segments: Vegetation Management Division and Industrial Equipment Division. The Vegetation Management Division includes all its agricultural activities and mowing and forestry/tree care operations, including Morbark and Dutch Power business. The Industrial Equipment Division includes its vocational truck business and other industrial operations, such as excavators, vacuum trucks, street sweepers, and snow removal equipment. The Company sells its products primarily through a network of independent dealers and distributors to governmental end-users, related independent contractors, as well as to the agricultural and commercial turf markets. The Company operates approximately 29 plants in North America, South America, Europe and Australia.

Price
Delayed
$147.64
Day's Change
0.92 (0.63%)
Bid
--
Ask
--
B/A Size
--
Day's High
147.66
Day's Low
145.50
Volume
(Below Average)

Today's volume of 17,717 shares is on pace to be lower than ALG's 10-day average volume of 38,473 shares.

17,717

KRBP 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm's Attorneys Before Oct. 4th Deadline in Securities Class Action

10:16 am ET October 2, 2022 (Globe Newswire) Print
KRBP 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm's Attorneys Before Oct. 4th Deadline in Securities Class ActionGlobeNewswireOctober 02, 2022

SAN FRANCISCO, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now.

Class Period: June 25, 2021 - Aug. 13, 2021

Lead Plaintiff Deadline: Oct. 4, 2022

Visit:https://www.hbsslaw.com/investor-fraud/KRBP

Contact An Attorney Now:KRBP@hbsslaw.com

844-916-0895

Kiromic BioPharma, Inc. (KRBP) Securities Class Action:

The litigation focuses on Kiromic's statements about its development of two cancer treatment product candidates, ALEXIS-PRO-1 and ALEXIS-ISO-1, allowing it to issue 8 million shares at $40 per share to investors, which secondary offering closed on or about July 1, 2021.

More specifically, Kiromic represented that it had applications to begin human clinical trials for the two new drug candidates, known as Investigational New Drug ("IND") applications, pending with FDA, and that the Company could commence clinical trials within 30 days of those IND applications unless the FDA imposed a clinical hold.

Unbeknownst to investors, the Company had received communications from the FDA on June 16 and 17, 2021, informing it that the FDA was placing the IND applications for its two candidate products on clinical hold.

On July 16, 2021, two weeks after the closing of the ordering, Kiromic disclosed that it had received "comments" from the FDA on its two IND applications.

Then, on Aug. 13, 2021, the Company clarified that the FDA had put the INDs on "clinical hold."

After the class period, on Jan. 27, 2022, the Company's CEO abruptly departed.

These events have driven the price of Kiromic shares sharply lower.

"We're focused on investors' losses and proving Kiromic misled investors by failing to disclose the June FDA clinical hold communications," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Kiromic and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Kiromic should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email KRBP@hbsslaw.com.

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:

Reed Kathrein, 844-916-0895



Primary Logo

comtex tracking

COMTEX_415741052/2010/2022-10-02T10:16:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.